Allosteric hemoglobin modifiers with nitric oxide releasing moiety

US9765017B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9765017-B2
Application numberUS-201415107962-A
CountryUS
Kind codeB2
Filing dateDec 22, 2014
Priority dateDec 27, 2013
Publication dateSep 19, 2017
Grant dateSep 19, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.

First claim

Opening claim text (preview).

We claim: 1. A compound having the general formula: wherein R1 and R2 are the same or different and are CH 3 , Cl, H, OCH 3 , or 5-carbon cyclic incorporating both R1 and R2; R3 is H, OH, COOH, or OC 2 H 5 ; R4 and R5 are the same or different and are H, CH 3 , cyclic incorporating both R4 and R5 and containing CH 3 substituents, OCH 3 , C 2 H 5 , phenyl, or unsubstituted phenyl; and R6 is a NO containing moiety selected from the group consisting of: 2. The compound of claim 1 having the formula: 3. A composition, comprising: one or more compounds as specified in claim 1 ; and a carrier. 4. The composition of claim 3 wherein said carrier is a liquid, and wherein said one or more compounds are dissolved or distributed in said liquid. 5. The composition of claim 4 wherein said liquid is an aqueous liquid. 6. The composition of claim 4 wherein said liquid is an oil. 7. The composition of claim 3 , wherein said carrier is a solid. 8. The composition of claim 3 wherein said carrier is a gas. 9. The composition of claim 8 wherein said gas is air.

Assignees

Inventors

Classifications

  • Antimalarials · CPC title

  • Drugs for immunological or allergic disorders · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Drugs for disorders of the cardiovascular system · CPC title

  • Antineoplastic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9765017B2 cover?
Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues…
Who is the assignee on this patent?
Univ Virginia Commonwealth
What technology area does this patent fall under?
Primary CPC classification C07C235/38. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).